Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause Upper respiratory tract infection? 3,306 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 3,306 reports of Upper respiratory tract infection have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.7% of all adverse event reports for ADALIMUMAB.

3,306
Reports of Upper respiratory tract infection with ADALIMUMAB
0.7%
of all ADALIMUMAB reports
401
Deaths
599
Hospitalizations

How Dangerous Is Upper respiratory tract infection From ADALIMUMAB?

Of the 3,306 reports, 401 (12.1%) resulted in death, 599 (18.1%) required hospitalization, and 194 (5.9%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

Yes, Upper respiratory tract infection is listed as a known adverse reaction in the official FDA drug label for ADALIMUMAB.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause Upper respiratory tract infection?

ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) SECUKINUMAB (1,339) LENALIDOMIDE (1,334)

Which ADALIMUMAB Alternatives Have Lower Upper respiratory tract infection Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection ADALIMUMAB Demographics